TrialResults-center.org
Search
Menu
Home
Search
Recent trials
Browse pathology
Browse treatment
About us
multiple myeloma
systematic review
meta-analysis
network meta-analysis
Select
immune checkpoint inhibition
All mechanism
proteasome inhibitor
All type of patient
newly diagnosed
uncoded clinical condition ***
--- uncoded (null)
carfilzomib
PD1 inhibitors
carfilzomib
nivolumab
pembrolizumab
Filter
hide ongoing
show ongoing
hide ongoing
all ROB
Show all trials
Show only trial at low risk of bias
Hide exploratory trials
all results
Show all trials
Show only trial with conclusive result
Group by
Group by...
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
MA
in first
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in second
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in third
Description
Synopsis
Comparison
Treatments
Patients
Characteristics
Method
Risk of bias
References
None
Tools
Indexation
Results
Global trial result
Main results
All results
All result tag
NCT results
death (overall survival) (5)
progression or death (progression free survival PFS) (2)
Options
Numeric
bar chart
forest plot
medians
Trial
Studied trt
Control trt
patients
tags
ROB
Trial result
death (overall survival)
progression or death (progression free survival PFS)
All mechanism
not classified
CLARION
NCT
carfilzomib
-
NCT01863550
NCT
carfilzomib
-
ELOQUENT - 1
NCT
Elotuzumab Lenalidomide Dexamethasone
Lenalidomide + Dexamethasone
Risk of bias
-
ELOQUENT - 2
NCT
Elotuzumab Lenalidomide Dexamethasone
Lenalidomide + Dexamethasone
-
MRC Myeloma IX
CTDa
MP
-
MM-015
NCT
MPR+R
MP
-
IFM 01/01
MPT
MP
-
IFM 99/06
NCT
MPT
MP
-
NCT01274403
NCT
MPT
MP
-
GIMEMA
NCT
MPT+T
MP
-
HOVON 49
MPT+T
MP
-
NMSG
MPT+T
MP
-
TMSG
NCT
MPT+T
MP
-
VISTA
NCT
VMP
MP
-
FIRST
NCT
Rd ou Rd18
MPT
-
EIA06 (NCT00602641)
NCT
MPR+R
MPT+T
-
NR 1997
PCAB+IFN-2a
PCAB
-
ASPIRE, 2015
NCT
carfilzomib
placebo (on top lenalidomide and dexamethasone)
Risk of bias
suggesting
-21%
ELOQUENT 2, 2015
NCT
elotuzumab
placebo (on top lenalidomide and dexamethasone)
Risk of bias
negative
-19%
NR 2013
MPR + CPR
Rd
-
NCT00911859
NCT
VMP + siltuximab
VMP
-
NR 2010
VMPT+VT
VMP
-
immune checkpoint inhibition
pembrolizumab
KEYNOTE-185, 2018
NCT
pembrolizumab, lenalidomide, dexametahsone
lenalidomide, dexamethasone
not eligible for ASCT
Risk of bias
remark
KEYNOTE-183, 2018
NCT
pembrolizumab + pomadoline + dexamethasone
pomadoline + dexamethasone
rrMM
Risk of bias
negative
proteasome inhibitor
carfilzomib
ENDEAVOR, 2016
NCT
carfilzomib
bortezomib
relapsed MM
Risk of bias
suggesting
-21%
-47%
ECOG-ACRIN
NCT
carfilzomib
bortezomid
-
CLARION
NCT
carfilzomib
bortezomid
-
ASPIRE, 2014
NCT
carfilzomib lenalidomide dexamethasone
lenalidomide and dexamethasone alone
relapsed MM
Risk of bias
suggesting
-21%
-31%
FOCUS, 2017
NCT
carfilzomib
low-dose corticosteroids
relapsed and refractory multiple myeloma (RRMM)
Risk of bias
negative
-3%
×
Modal title